company background image
GLENMARK logo

Glenmark Pharmaceuticals NSEI:GLENMARK Voorraadrapport

Laatste prijs

₹1.48k

Marktkapitalisatie

₹417.1b

7D

-3.6%

1Y

87.9%

Bijgewerkt

23 Nov, 2024

Gegevens

Financiële gegevens bedrijf +

Glenmark Pharmaceuticals Limited

NSEI:GLENMARK Voorraadrapport

Marktkapitalisatie: ₹417.1b

GLENMARK Overzicht aandelen

Glenmark Pharmaceuticals Limited ontwikkelt, produceert en verkoopt samen met haar dochterondernemingen generieke geneesmiddelen, speciale producten en OTC-geneesmiddelen in India, Noord-Amerika, Latijns-Amerika en Europa. Meer informatie

GLENMARK fundamentele analyse
Sneeuwvlok Score
Waardering2/6
Toekomstige groei4/6
Prestaties in het verleden0/6
Financiële gezondheid5/6
Dividenden2/6

Beloningen

De winst zal naar verwachting met 70.35% per jaar groeien

Risicoanalyse

Geen risico's gedetecteerd voor GLENMARK uit onze risicocontroles.

Glenmark Pharmaceuticals Limited Concurrenten

GlaxoSmithKline Pharmaceuticals

BSE:500660

₹409.1b

Ipca Laboratories

NSEI:IPCALAB

₹403.7b

Piramal Pharma

NSEI:PPLPHARMA

₹331.6b

Ajanta Pharma

NSEI:AJANTPHARM

₹369.7b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Glenmark Pharmaceuticals
Historische aandelenkoersen
Huidige aandelenkoers₹1,478.20
52 Week Hoogtepunt₹1,830.95
52 Week Laag₹764.50
Bèta0.88
11 maand verandering-11.73%
3 maanden verandering-12.36%
1 Jaar Verandering87.85%
33 jaar verandering177.75%
5 jaar verandering338.24%
Verandering sinds IPO5,351.10%

Recent nieuws en updates

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Oct 26
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Sep 06
Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Recent updates

Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

Oct 26
Pinning Down Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) P/S Is Difficult Right Now

This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Sep 21
This Is Why Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation Looks Appropriate

Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Sep 06
Glenmark Pharmaceuticals (NSE:GLENMARK) Is Paying Out A Dividend Of ₹2.50

Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 06
Calculating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Jun 16
Does Glenmark Pharmaceuticals (NSE:GLENMARK) Have A Healthy Balance Sheet?

Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

May 08
Is Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Expensive For A Reason? A Look At Its Intrinsic Value

Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Mar 09
Glenmark Pharmaceuticals (NSE:GLENMARK) Takes On Some Risk With Its Use Of Debt

Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Dec 07
Is Glenmark Pharmaceuticals (NSE:GLENMARK) Using Too Much Debt?

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 23
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Sep 17
Glenmark Pharmaceuticals (NSE:GLENMARK) Will Pay A Dividend Of ₹2.50

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 30
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Aug 28
A Look At The Intrinsic Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

Jul 03
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Is Taking Some Risk With Its Debt

A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

May 28
A Look At The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Mar 22
Glenmark Pharmaceuticals (NSE:GLENMARK) Has A Somewhat Strained Balance Sheet

Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

Feb 14
Estimating The Fair Value Of Glenmark Pharmaceuticals Limited (NSE:GLENMARK)

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Oct 12
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 37% Undervalued

Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Sep 21
Shareholders Will Probably Hold Off On Increasing Glenmark Pharmaceuticals Limited's (NSE:GLENMARK) CEO Compensation For The Time Being

Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

Aug 29
Glenmark Pharmaceuticals (NSE:GLENMARK) Has Announced A Dividend Of ₹2.50

We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

Jun 20
We Think Glenmark Pharmaceuticals (NSE:GLENMARK) Can Stay On Top Of Its Debt

There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

Jun 04
There May Be Reason For Hope In Glenmark Pharmaceuticals' (NSE:GLENMARK) Disappointing Earnings

An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

May 05
An Intrinsic Calculation For Glenmark Pharmaceuticals Limited (NSE:GLENMARK) Suggests It's 27% Undervalued

If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Mar 25
If You Like EPS Growth Then Check Out Glenmark Pharmaceuticals (NSE:GLENMARK) Before It's Too Late

Rendement voor aandeelhouders

GLENMARKIN PharmaceuticalsIN Markt
7D-3.6%0.5%0.5%
1Y87.9%42.5%27.5%

Rendement versus industrie: GLENMARK overtrof de Indian Pharmaceuticals industrie, die het afgelopen jaar een rendement 42.5 % opleverde.

Rendement versus markt: GLENMARK overtrof de Indian markt, die het afgelopen jaar een rendement opleverde van 27.5 %.

Prijsvolatiliteit

Is GLENMARK's price volatile compared to industry and market?
GLENMARK volatility
GLENMARK Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement6.0%
Market Average Movement6.1%
10% most volatile stocks in IN Market9.1%
10% least volatile stocks in IN Market4.0%

Stabiele aandelenkoers: GLENMARK heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 4% ) van GLENMARK is het afgelopen jaar stabiel geweest.

Over het bedrijf

OpgerichtWerknemersCEOWebsite
197714,989Glenn Saldanhawww.glenmarkpharma.com

Glenmark Pharmaceuticals Limited ontwikkelt, produceert en verkoopt samen met haar dochterondernemingen generieke geneesmiddelen, speciale producten en OTC-geneesmiddelen in India, Noord-Amerika, Latijns-Amerika en Europa. Het bedrijf levert merk- en generieke formuleringen in de therapeutische gebieden dermatologie, luchtwegen, oncologie, cardiologie, diabetes, gynaecologie, gastro-enterologie en anti-infectiva in de doseringsvormen complexe injectables en biologische geneesmiddelen, orale vaste stoffen, vloeistoffen, topische producten, druppels en ademhalings/MDI/DPI/nasale sprays. De productpijplijn omvat ISB 2001, een BCMA x CD38 x CD3 trispecifieke betrokkenheid door antilichamen gebaseerd op de T-celreceptor trispecifieke antilichaam, dat in Fase 1 klinische studie is voor de indicatie van recidief/refractair multipel myeloom; ISB 1442, een CD38 x CD47 bispecifieke binding door antilichamen gebaseerd op de T celreceptor biparatopisch bispecifiek antilichaam, dat zich in Fase 1 van het klinisch onderzoek bevindt voor de behandeling van recidief/refractair multipel myeloom en acute myeloïde leukemie; en GRC 65327, een Cbi-b remmer, die zich in preklinisch onderzoek bevindt voor de indicatie van solide tumoren.

Glenmark Pharmaceuticals Limited Samenvatting

Hoe verhouden de winst en inkomsten van Glenmark Pharmaceuticals zich tot de beurswaarde?
GLENMARK fundamentele statistieken
Marktkapitalisatie₹417.13b
Inkomsten(TTM)-₹10.18b
Inkomsten(TTM)₹130.80b

3.2x

P/S-verhouding

-41.0x

Koers/Winstverhouding

Is GLENMARK overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
GLENMARK resultatenrekening (TTM)
Inkomsten₹130.80b
Kosten van inkomsten₹43.73b
Brutowinst₹87.06b
Overige uitgaven₹97.25b
Inkomsten-₹10.18b

Laatst gerapporteerde inkomsten

Sep 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)-36.09
Brutomarge66.56%
Nettowinstmarge-7.79%
Schuld/Eigen Vermogen Verhouding18.5%

Hoe presteerde GLENMARK op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

0.2%

Huidig dividendrendement

-4%

Uitbetalingsratio